𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A clinical exploratory study with itolizumab, an anti-CD6 monoclonal antibody, in patients with rheumatoid arthritis

✍ Scribed by Rodriguez, Pedro C.; Torres-Moya, Roberto; Reyes, Gil; Molinero, Claudino; Prada, Dinorah; Lopez, Ana M.; Hernandez, Isabel M.; Hernandez, Maria V.; Martinez, Jose P.; Hernandez, Xochel; Casaco, Angel; Ramos, Mayra; Avila, Yisel; Barrese, Yinet; Montero, Enrique; Hernandez, Patricia

Book ID
123471538
Publisher
Elsevier
Year
2012
Tongue
English
Weight
416 KB
Volume
2
Category
Article
ISSN
2211-2839

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A randomized controlled trial with an an
A randomized controlled trial with an anti-CCL2 (anti–monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis
✍ Jasper J. Haringman; Danielle M. Gerlag; Tom J. M. Smeets; Dominique Baeten; Fil πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 73 KB πŸ‘ 2 views

## Abstract ## Objective Chemokines such as CCL2/monocyte chemotactic protein 1 (MCP‐1) play a key role in leukocyte migration and are potential targets in the treatment of chronic inflammatory disorders. The objective of this study was to evaluate the effects of human anti–CCL2/MCP‐1 monoclonal a